登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《SSRN，3月17日，Molecular Modeling of Isolated Phytochemicals from Ocimum Sanctum Towards Exploring Potential Inhibitors of SARS Coronavirus Main Protease and Papain-Like Protease to Treat COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-21

  • Molecular Modeling of Isolated Phytochemicals from Ocimum Sanctum Towards Exploring Potential Inhibitors of SARS Coronavirus Main Protease and Papain-Like Protease to Treat COVID-19

    Posted: 17 Mar 2020

    Krishna Kumar Varshney

    MIT College of Pharmacy MIT Group of Institutions, Moradabad

    Megha Varshney

    BBDIT College of Pharmacy, Ghaziabad

    Bishamber Nath

    MET Faculty of Pharmacy, MIT Group of Institutions, Moradabad

    Date Written: March 14, 2020

    Abstract

    Background: In December 2019, there was a cluster of pneumonia cases in China. Investigations found that it was caused by a previously unknown virus, now named the 2019 Novel Coronavirus (CoV). CoV are a large group of viruses; they consist of a core of genetic material surrounded by an envelope of proteins spikes. There are different types of CoV that causes respiratory and sometimes gastrointestinal symptoms. Respiratory symptoms can range from the common cold to pneumonia and in most people the symptoms tend to be mild. However, there are some types of CoV that can cause severe disease, these include SARS - CoV, identified in China 2003, and MERS - CoV, that was first identified in Saudi Arabia in 2012. The 2019 CoV was first identified in China 2019. Currently 146, 305 cases has been reported for CoV included 5441 case for death, widely. To overcome this epidemiology, investigator find CoV main protease and papain-like protease, which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design.

  • 原文来源：https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3554371
94浏览量
原文链接
相关报告

  • 《ChemRxiv，2月19日，Potential Inhibitors Against Papain-like Protease of Novel Coronavirus (COVID-19) from FDA Approved Drugs》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-20
    • Potential Inhibitors Against Papain-like Protease of Novel Coronavirus (COVID-19) from FDA Approved Drugs Preprint submitted on 17.02.2020, 01:03 and posted on 19.02.2020, 05:54 by Rimanshee Arya Amit Das Vishal Prashar Mukesh Kumar The cases of 2019 novel coronavirus (COVID-19) infection have been continuously increasing ever since its outbreak in China last December. Currently, there are no approved drugs to treat the infection. In this scenario, there is a need to utilize the existing repertoire of FDA approved drugs to treat the disease. The rational selection of these drugs could be made by testing their ability to inhibit any COVID-19 proteins essential for viral life-cycle. We chose one such crucial viral protein, the papain-like protease (PLpro), to screen the FDA approved drugs in silico. The homology model of the protease was built based on the SARS-coronavirus PLpro structure, and the drugs were docked in S3/S4 pockets of the active site of the enzyme. In our docking studies, fifteen FDA approved drugs, including chloroquine and formoterol, bind the target enzyme with significant affinity and good geometry, suggesting their potential to be utilized against the virus. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    117浏览量
    原文链接

  • 《Nature，2月2日，Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-25
    • Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors Jerzy Osipiuk, Saara-Anne Azizi, Steve Dvorkin, Michael Endres, Robert Jedrzejczak, Krysten A. Jones, Soowon Kang, Rahul S. Kathayat, Youngchang Kim, Vladislav G. Lisnyak, Samantha L. Maki, Vlad Nicolaescu, Cooper A. Taylor, Christine Tesar, Yu-An Zhang, Zhiyao Zhou, Glenn Randall, Karolina Michalska, Scott A. Snyder, Bryan C. Dickinson & Andrzej Joachimiak Nature Communications volume 12, Article number: 743 (2021) Abstract The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals. PLpro is an attractive target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses. We report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the SARS-CoV-2 enzyme. We determined the high resolution structure of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors. This collection of structures details inhibitors recognition and interactions providing fundamental molecular and mechanistic insight into PLpro. All compounds inhibit the peptidase activity of PLpro in vitro, some block SARS-CoV-2 replication in cell culture assays. These findings will accelerate structure-based drug design efforts targeting PLpro to identify high-affinity inhibitors of clinical value.
    192浏览量
    原文链接